Probiotics: Support gut health during GLP-1 treatment
[RELATED: New Medicare GLP-1 Program Excludes TRICARE For Life Beneficiaries] Researchers at Washington University School of Medicine have increasingly studied whether GLP-1 medications, originally developed for diabetes and later approved for obesity, could also help treat substance use disorders
Even though obesity and other metabolic disorders are known to be higher in IBD patients, medications to treat obesity in this population are underutilized
Mean increases in resting heart rate have been observed in randomized clinical trials of semaglutide and are documented in FDA prescribing information
This makes BPC-157 particularly valuable for individuals with IBD, leaky gut syndrome, and even those recovering from accidental gluten exposure in celiac disease
You know, you take a drug like ozempic, its extremely expensive